Skip to main content

Table 3 Risk of DFR according to PT’s characteristics

From: Early persistence on therapy impacts drug-free remission: a case-control study in a cohort of Hispanic patients with recent-onset rheumatoid arthritis

 

Model 1

Model 2

Model 3

HR (95% CI), p value

% of the patient follow-up PT

1.00 (0.98–1.02), 0.659

1.00 (0.98–1.02), 0.959

 

Early PT

1.79 (0.59–5.46), 0.303

3.84 (1.13–13.07), 0.031

3.16 (1.14–8.77), 0.027

Baseline SF-36 physical component score

0.99 (0.96–1.02), 0.47

 

0.98 (0.96–1.01), 0.136

Cumulative (up to the first 2 years of follow-up) number of DMARDs/patient

 

0.19 (0.08–0.45), ≤ 0.001

0.12 (0.07–0.41), ≤ 0.001

  1. HR hazard ratio, CI confidence interval, PT persistence on therapy, SF-36 Short Form 36, DMARDs disease-modifying anti-rheumatic drugs